Autologous stem-cell transplantation (autoSCT) is considered a standard treatment of non-frail patients with mantle cell lymphoma (MCL), but little is known about outcome of MCL patients relapsing after autoSCT. We therefore sought to analyse the outcome after autoSCT failure and the efficacy of a rescue stem-cell transplantation (SCT) in this setting. Patients with MCL were eligible if they had relapsed after autoSCT performed between 2000 and 2009. A total of 1054 patients could be identified in the EBMT registry. By contacting the transplant centres, a full dataset could be retrieved for 360 patients. Median overall survival (OS) after relapse of the whole study group was 19 months. A long (> 12 months) interval between autoSCT and re...
Mantle cell lymphoma (MCL) is an incurable disease with a highly variable clinical course. The progn...
Objective: The aim of the first Nordic mantle cell lymphoma (MCL) protocol was to study the clinical...
INTRODUCTION Mantle cell lymphoma (MCL) patients can be treated with intensive induction therapy,...
Autologous stem-cell transplantation (autoSCT) is considered a standard treatment of non-frail patie...
Reduced-intensity allogeneic stem cell transplantation (RIST) is usually reserved for patients with ...
Reduced-intensity allogeneic stem cell transplantation (RIC-AlloSCT) is being increasingly considere...
Reduced intensity Allogeneic stem cell transplantation (RIC-AlloSCT) is being increasingly considere...
International audiencePoly-chemotherapy plus rituximab followed by autologous stem cell transplantat...
Autologous hematopoietic stem cell transplantation (auto-HSCT) is the standard of care for patients ...
AbstractOutcomes with autologous hematopoietic cell transplantation (auto HCT) for relapsed and/or r...
In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma (DLBCL) were cons...
Introduction: In patients with mantle cell lymphoma (MCL), long-term remissions can be achieved by s...
Purpose To analyze the outcome, including nonrelapse mortality (NRM), relapse rate (RR), progression...
Mantle cell lymphoma (MCL) is an incurable disease with a highly variable clinical course. The progn...
Objective: The aim of the first Nordic mantle cell lymphoma (MCL) protocol was to study the clinical...
INTRODUCTION Mantle cell lymphoma (MCL) patients can be treated with intensive induction therapy,...
Autologous stem-cell transplantation (autoSCT) is considered a standard treatment of non-frail patie...
Reduced-intensity allogeneic stem cell transplantation (RIST) is usually reserved for patients with ...
Reduced-intensity allogeneic stem cell transplantation (RIC-AlloSCT) is being increasingly considere...
Reduced intensity Allogeneic stem cell transplantation (RIC-AlloSCT) is being increasingly considere...
International audiencePoly-chemotherapy plus rituximab followed by autologous stem cell transplantat...
Autologous hematopoietic stem cell transplantation (auto-HSCT) is the standard of care for patients ...
AbstractOutcomes with autologous hematopoietic cell transplantation (auto HCT) for relapsed and/or r...
In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma (DLBCL) were cons...
Introduction: In patients with mantle cell lymphoma (MCL), long-term remissions can be achieved by s...
Purpose To analyze the outcome, including nonrelapse mortality (NRM), relapse rate (RR), progression...
Mantle cell lymphoma (MCL) is an incurable disease with a highly variable clinical course. The progn...
Objective: The aim of the first Nordic mantle cell lymphoma (MCL) protocol was to study the clinical...
INTRODUCTION Mantle cell lymphoma (MCL) patients can be treated with intensive induction therapy,...